These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28594175)

  • 1. Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.
    Matthew AN; Zephyr J; Hill CJ; Jahangir M; Newton A; Petropoulos CJ; Huang W; Kurt-Yilmaz N; Schiffer CA; Ali A
    J Med Chem; 2017 Jul; 60(13):5699-5716. PubMed ID: 28594175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Xue W; Ban Y; Liu H; Yao X
    J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.
    Matthew AN; Zephyr J; Nageswara Rao D; Henes M; Kamran W; Kosovrasti K; Hedger AK; Lockbaum GJ; Timm J; Ali A; Kurt Yilmaz N; Schiffer CA
    mBio; 2020 Mar; 11(2):. PubMed ID: 32234812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
    Xue W; Wang M; Jin X; Liu H; Yao X
    Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease.
    Matthew AN; Leidner F; Newton A; Petropoulos CJ; Huang W; Ali A; KurtYilmaz N; Schiffer CA
    Structure; 2018 Oct; 26(10):1360-1372.e5. PubMed ID: 30146168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants.
    Nageswara Rao D; Zephyr J; Henes M; Chan ET; Matthew AN; Hedger AK; Conway HL; Saeed M; Newton A; Petropoulos CJ; Huang W; Kurt Yilmaz N; Schiffer CA; Ali A
    J Med Chem; 2021 Aug; 64(16):11972-11989. PubMed ID: 34405680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
    Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
    PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.
    Welsch C; Shimakami T; Hartmann C; Yang Y; Domingues FS; Lengauer T; Zeuzem S; Lemon SM
    Gastroenterology; 2012 Mar; 142(3):654-63. PubMed ID: 22155364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
    Summa V; Ludmerer SW; McCauley JA; Fandozzi C; Burlein C; Claudio G; Coleman PJ; Dimuzio JM; Ferrara M; Di Filippo M; Gates AT; Graham DJ; Harper S; Hazuda DJ; Huang Q; McHale C; Monteagudo E; Pucci V; Rowley M; Rudd MT; Soriano A; Stahlhut MW; Vacca JP; Olsen DB; Liverton NJ; Carroll SS
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4161-7. PubMed ID: 22615282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
    Lampa A; Ehrenberg AE; Gustafsson SS; Vema A; Kerblom E; Lindeberg G; Karlén A; Danielson UH; Sandström A
    Bioorg Med Chem; 2010 Jul; 18(14):5413-24. PubMed ID: 20541424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
    Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
    J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
    Ren J; Ojeda I; Patel M; Johnson ME; Lee H
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
    Wang AX; Chen J; Zhao Q; Sun LQ; Friborg J; Yu F; Hernandez D; Good AC; Klei HE; Rajamani R; Mosure K; Knipe JO; Li D; Zhu J; Levesque PC; McPhee F; Meanwell NA; Scola PM
    Bioorg Med Chem Lett; 2017 Feb; 27(3):590-596. PubMed ID: 28011221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V.
    Ortqvist P; Vema A; Ehrenberg AE; Dahl G; Rönn R; Akerblom E; Karlén A; Danielson UH; Sandström A
    Antivir Ther; 2010; 15(6):841-52. PubMed ID: 20834096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
    Boonma T; Nutho B; Darai N; Rungrotmongkol T; Nunthaboot N
    J Biomol Struct Dyn; 2022 Aug; 40(12):5283-5294. PubMed ID: 33430709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
    Ezat AA; Elshemey WM
    Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
    El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF
    J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V).
    Ezat AA; El-Bialy NS; Mostafa HI; Ibrahim MA
    Protein J; 2014 Feb; 33(1):32-47. PubMed ID: 24374429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.